Literature DB >> 1350718

Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.

M R Luquin1, J Laguna, J A Obeso.   

Abstract

Stimulation of D1 striatal receptors has been proposed as the main mechanism mediating levodopa-induced dyskinesia in Parkinson's disease. We used (+)-PHNO, a selective D2 agonist, as the only treatment in 6 cynomolgus monkeys made parkinsonian by repeated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. All animals developed choreic dyskinesia after a mean treatment period of 12.8 days (range, 1-29). Administration of the D1 antagonist SCH-23390 1 hour before administration of (+)-PHNO did not change the dyskinesia. These results indicate that drug-induced dyskinesia in a primate model of Parkinson's disease is not solely induced by D1 receptor activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350718     DOI: 10.1002/ana.410310514

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.

Authors:  Yunmin Ding; Jacqueline Restrepo; Lisa Won; Dong-Youn Hwang; Kwang-Soo Kim; Un Jung Kang
Journal:  Neurobiol Dis       Date:  2007-04-10       Impact factor: 5.996

2.  Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.

Authors:  Ettel Keifman; Irene Ruiz-DeDiego; Diego Esteban Pafundo; Rodrigo Manuel Paz; Oscar Solís; Mario Gustavo Murer; Rosario Moratalla
Journal:  Br J Pharmacol       Date:  2019-05-21       Impact factor: 8.739

Review 3.  Comparative tolerability of the newer generation antiparkinsonian agents.

Authors:  D Lambert; C H Waters
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 4.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

5.  A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys.

Authors:  Goichi Beck; Shunsuke Maehara; Phat Ly Chang; Stella M Papa
Journal:  Mov Disord       Date:  2018-03-06       Impact factor: 10.338

Review 6.  Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.

Authors:  Lisa F Potts; Hao Wu; Arun Singh; Irene Marcilla; Maria R Luquin; Stella M Papa
Journal:  Exp Neurol       Date:  2013-09-23       Impact factor: 5.330

Review 7.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 8.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

9.  Quantitative autoradiographic study on receptor regulation in the basal ganglia in rat model of levodopa-induced motor complications.

Authors:  Yan Xu; Zhentao Zhang; Kairong Qin; Stella M Papa; Xuebing Cao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

10.  Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.

Authors:  Myriam Heiman; Adrian Heilbut; Veronica Francardo; Ruth Kulicke; Robert J Fenster; Eric D Kolaczyk; Jill P Mesirov; Dalton J Surmeier; M Angela Cenci; Paul Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.